Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Cirius Therapeutics to Present Late-Breaking Poster at The International Liver Congress

Cirius Therapeutics
Posted on: 29 Mar 18
Cirius Therapeutics to Present Late-Breaking Poster at The International Liver Congress

PR Newswire

SAN DIEGO and KALAMAZOO, Mich., March 29, 2018

SAN DIEGO and KALAMAZOO, Mich., March 29, 2018 /PRNewswire/ -- Cirius Therapeutics announced today that it will present a late-breaking poster describing the activity of the company's lead drug MSDC-0602K in a three-dimensional bioprinted human tissue model of NASH at The International Liver Congress™ 2018, occurring in Paris, France from April 11-15, 2018 at the Paris Convention Center.

The poster, entitled "A human in vitro three-dimensional bioprinted tissue system can be used to model nutritional damage and protective effects of MSDC-0602K, a novel modulator of the mitochondrial pyruvate carrier" will be presented in the Poster Late Breakers session on Thursday, April 12, 2018, in hall 7.2 from 9 AM to 5 PM. The work will be presented by Dr. Jerry Colca from Cirius Therapeutics and includes contributions from Organovo.

About MSDC-0602K

MSDC-0602K is an oral, once-daily next-generation small molecule that restores metabolic balance at its root — through mitochondrial function — and therefore increases the body's sensitivity to insulin, the hormone that is the master regulator of metabolism. MSDC-0602K, which modulates the entry of pyruvate into the mitochondria, has the potential to correct the metabolic disturbance that is a proximate cause of NASH. Cirius is currently enrolling the EMMINENCE trial, a Phase 2b study of MSDC-0602K in NASH. This randomized study is comparing three doses of MSDC-0602K to placebo in NASH patients with fibrosis, and the study includes endpoints identified as suitable for registration studies based on current FDA guidelines.

About Cirius Therapeutics

Cirius Therapeutics is a clinical-stage pharmaceutical company focused on developing therapies to treat liver disease. The company's lead product is MSDC-0602K, a molecule that restores metabolic balance at its root – through mitochondrial function – and therefore reduces insulin resistance. Cirius is actively enrolling patients in a Phase 2b clinical trial called the EMMINENCE trial, to evaluate MSDC-0602K in patients with NASH and liver fibrosis.  For more information about Cirius Therapeutics, visit www.ciriustx.com.

 

View original content:http://www.prnewswire.com/news-releases/cirius-therapeutics-to-present-late-breaking-poster-at-the-international-liver-congress-300621456.html

SOURCE Cirius Therapeutics

PR Newswire
www.prnewswire.com

Last updated on: 29/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.